Abstract:OBJECTIVES:To compare the clinical effect of low molecular weight heparin (LMWH) and regional citrate anticoagulation (RCA) in continuous renal replacement therapy (CRRT) after heart valve replacement. METHODS:Retrospective analysis of clinical data from 60 patients undergoing continuous renal replacement therapy after heart valve replacement in Peking University Shenzhen Hospital from January 2015 to July 2019, including 35 males and 25 females, aged (58.83 ±16.36) years. The patients were divided into a LMWH group and a RCA group according to the anticoagulation regimen, with 30 patients in each group. The 24 h postoperative drainage volume (pericardium, mediastinum), postoperative ventilator use time and ICU stay time, incidence of postoperative respiratory tract bleeding and gastrointestinal bleeding, postoperative skin ecchymosis incidence and mortality between the 2 groups were compared; the thromboplastin time (APTT), fibrinogen (FIB), thrombin time (TT), prothrombin time (PT), international normalized ratio (INR), and PLT between the 2 groups after anticoagulation treatment were compared; the service life of dialysis filters and CRRT time between the 2 groups were compared; and the levels of urea nitrogen and serum creatinine between the 2 groups before and after treatment were also compared. RESULTS:After anticoagulant treatment, the RCA group had less 24 h postoperative drainage volume than the LMWH group, shorter ventilator use time, ICU stay time, and hospitalization days than the LMWH group, and lower respiratory tract bleeding and gastrointestinal bleeding incidence than the LMWH group, with significant differences (all P<0.05); there was no significant difference in the incidence of skin ecchymosis and mortality after treatment between the 2 groups (all P>0.05); there was no significant difference in APTT, FIB, and TT between the 2 groups (all P>0.05); the PT and INR of the RCA group were higher than those in the LMWH group, while the PLT of RCA group was lower than that in the LMWH group, with significant differences (all P<0.05); there was no significant difference in CRRT time between the two groups (P=0.073). After the treatment, there were no significant differences in urea nitrogen and serum creatinine levels between the 2 groups (all P>0.05). CONCLUSIONS:CRRT after cardiac valve replacement with RCA can effectively reduce pericardial and mediastinal drainage, reduce the risk of bleeding, shorten the time of ventilator use and ICU stay, and promote postoperative recovery of patients, which have positive significance for reducing the burden on patients and their families.

Comparison of the two intravenous methods for low molecular weight heparin administration in continuous renal replacement therapy

Evaluation of the Anticoagulant Effect of Low-Molecular-weight Heparins Based on the Anti-Xa Level During Haemodialysis

ACD-A Solution As Anticoagulant During Continuous Renal Replacement Therapy in High Risk Bleeding Patients

Comparison of Curative Effect Between Different Anticoagulation Regimens in Continuous Renal Replacement Therapy after Cardiac Valve Replacement.

Regional Citrate Plus Low Dose of Low Molecular Weight Heparins in Continuous Veno-Venous Hemofiltration

Application of regional citrate anticoagulation (RCA) in continuous renal replacement therapy (CRRT) in patients with high risk of bleeding

Comparison of Anticoagulant Effect of Low-Molecular-Weight Heparin Sodium and Sodium Citrate on Patients with Severe Acute Kidney Injury Treated by Continuous Renal Replacement Therapy

Application of Continuous Veno-Venous Hemodiafiltration to Severely Acute Renal Failure after Cardiac Surgery

Analysis of the Extracorporeal Anticoagulation Effect of Modified Citrate Infusion During Continuous Renal Replacement Therapy in Critically Ill Patients

Using nafamostat mesilate anticoagulation for continuous renal replacement therapy in high bleeding risk patients: a systematic review and meta-analysis

Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial

A mode of CVVH with regional citrate anticoagulation compared to no anticoagulation for acute kidney injury patients at high risk of bleeding

Randomized Controlled Trial to Evaluate Regional Citrate Anticoagulation Plus Low-Dose of Dalteparin in Continuous Veno-Venous Hemofiltration

Continuous Venovenous Hemofi Ltration with Citrate Based,calcium-,Mag Nesium-Free Replacement Solution in Acut E Renal Failure Patients at High Risk of Bleeding

The Effect of Substitution Fluid Rate on the Prognosis of Critical Acute Kidney Injury Patients Treated with Continuous Veno-Venous Hemorfltration Therapy

The effect of continuous renal replacement therapy in patients with acute kidney injury on the serum levels of urea,creatinine and cystatin C

Comparison of low-molecular weight heparin with low-dose heparin in treating hemodialysis patients at high risk of bleeding

Intensive- Vs Less-Intensive-dose Continuous Renal Replacement Therapy for the Intensive Care Unit–related Acute Kidney Injury: A Meta-Analysis and Systematic Review

Regional Citrate Anticoagulation in Heparin-Contraindicative Critically Ill Patients During Continuous Venovenous Hemofiltration

COMPARATIVE STUDY OF SOLUTES CLEARANCES BETWEEN VARIOUS CONTINUOUS RENAL REPLACEMENT THERAPY METHODS

Variables Associated with Circuit Life Span in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy: a Prospective Observational Study.